Market Access UK pharma policy at a turning point: NICE threshold reform, ... The ICER threshold increase is expected to allow an additional three to five medicines or indications each year to be recommended for NHS use.
R&D The SPC waiver: How do we restore the intended balance betwe... Biosimilars promote cost-effective solutions to critical healthcare challenges.
Views & Analysis Huge scale of Brexit threat to Europe’s medicines supplies r... New survey reveals the huge task facing pharma in keeping medicines moving around Europe after Brexit.
News Halozyme diversifies in drug delivery with Surf Bio buy Halozyme has expanded its portfolio of drug delivery technologies for a second time in a few months with the acquisition of Surf Bio for up to $400m.
Sales & Marketing Sponsored How to meet your physicians where they are online A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.